Novavax to Highlight RSV Program Data at Two Upcoming Meetings

Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.

Oral presentation details are as follows: 

IDWeek 2018 Meeting
Title:		Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
Presenter:		Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:		213. Late Breaker Oral Abstracts: Influenza and Vaccines
Date and Time:		Saturday, October 6, 11:20 a.m. P.T.
Location:		Moscone Convention Center S 152-154
11th International Respiratory Syncytial Virus Symposium
Title:		Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant
Presenter:		Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc.
Session:		5. Advancements in RSV Vaccines
Date and Time:		Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T.
Location:		Omni Grove Park Inn
Title:		Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants
Presenter:		Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:		12. Maternal Immunity & Maternal Vaccination
Date:		Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T.
Location:		Omni Grove Park Inn

Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on Thursday, November 1, 11:30 a.m. – 12:30 p.m. E.T. and on Friday, November 2, 8:30 p.m. – 10:00 p.m. E.T. at the Omni Grove Park Inn.

Title:		Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization
Presenter:		Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc.
Title:		Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody
Presenter:		Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc.
Title:		In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine
Presenter:		Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc.
Title:		Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats
Presenter:		Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc.
Title:		Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection
Presenter:		Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:      

InvestorsNovavax, Inc.Erika TrahanSenior Manager, Investor & Public [e-mail]240-268-2000

Westwicke PartnersJohn [e-mail]443-213-0506

MediaSam BrownMike [e-mail]312-961-2502